MNKDMANNKIND CORP
Pharmaceutical Preparations
- Revenue
- $349M
- 22% YoY
- Operating margin
- 11.1%
- 56% YoY
- EBITDA
- $51M
- 36% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- 5.2×
- $266M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear311% of net incomeCash flow under 80% of net income
- Dilutive SBCClear7% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear9% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $75M | $100M | $199M | $286M | $349M | 22% |
| Operating income | −$47M | −$64M | $9M | $73M | $39M | 47% |
| Net income | −$81M | −$87M | −$12M | $28M | $6M | 79% |
| Operating cash flow | −$62M | −$81M | $34M | $43M | $18M | 57% |
| Capex | $11M | $8M | $42M | $10M | $5M | 53% |
| Stock-based comp | $12M | $13M | $18M | $21M | $24M | 13% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $256K · 2
- Net
- −$256K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $9M | $752K | 181 | 125 |
| FY2024 | $9M | $23M | 205 | 93 |
| FY2023 | $7M | $97K | 116 | 94 |
| FY2022 | $4M | $10M | 168 | 90 |
| FY2021 | $4M | $7M | 140 | 100 |